|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
subcutaneous injection
|
|
gptkbp:clinical_trial
|
Phase III
ongoing studies
|
|
gptkbp:clinical_use
|
add-on therapy
not for acute asthma attacks
|
|
gptkbp:contraindication
|
hypersensitivity to mepolizumab
|
|
gptkbp:dosage_form
|
injection
100 mg once every 4 weeks
|
|
gptkbp:effective_date
|
2015-11-04
|
|
gptkbp:financial_support
|
available through manufacturer
|
|
gptkbp:formulation
|
single-use prefilled syringe
single-use autoinjector
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nucala
|
|
gptkbp:indication
|
severe asthma
|
|
gptkbp:ingredients
|
gptkb:mepolizumab
|
|
gptkbp:is_monitored_by
|
eosinophil counts
asthma control
|
|
gptkbp:manufacturer
|
gptkb:Glaxo_Smith_Kline
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
inhibits IL-5 signaling
|
|
gptkbp:patient_population
|
adults and children 6 years and older
|
|
gptkbp:pharmacokinetics
|
gptkb:monoclonal_antibody
long half-life
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:provides_guidance_on
|
included in asthma management guidelines
|
|
gptkbp:related_products
|
gptkb:Fasenra
gptkb:Dupixent
gptkb:Xolair
Tezspire
|
|
gptkbp:requires
|
available online
|
|
gptkbp:research
|
studies on combination therapies
studies on efficacy in different populations
studies on long-term effects
|
|
gptkbp:route_of_administration
|
subcutaneous
|
|
gptkbp:side_effect
|
fatigue
headache
back pain
increased risk of infections
injection site reactions
serious allergic reactions
nasopharyngitis
|
|
gptkbp:storage
|
refrigerated
protected from light
|
|
gptkbp:targets
|
IL-5
|
|
gptkbp:used_for
|
gptkb:eosinophilic_granulomatosis_with_polyangiitis
gptkb:asthma
|
|
gptkbp:bfsParent
|
gptkb:GSK
|
|
gptkbp:bfsLayer
|
4
|